BIOTECanada Announces Addition of Directors to Board of Directors

TORONTO–(BUSINESS WIRE)–Following the Annual General Meeting of BIOTECanada, the Board of Directors is announcing the election of three additional Directors to the Board. The new Directors include:

• Colleen Coxson, Country Manager, Alnylam Pharmaceuticals
• Rhonda Pacheco, President and General Manager, Eli Lilly Canada
• Nancy Pei, Partner, Smart & Biggar

“On behalf of the BIOTECanada team and the member companies, I extend appreciation to the outgoing Directors John Norman (Partner Gowling WLG Canada LLP), and Shermaine Tilley, Managing Partner (CTI Life Sciences Fund) for their time and commitment to the Association,” commented Andrew Casey President and CEO BIOTECanada. “Canada’s biotech ecosystem is built on a reputation of strong scientific research and includes a diverse mix of early-stage companies, universities, incubators/accelerators, research centres, investors, and multinational pharmaceutical/biotech companies. I look forward to working with the Board as we continue our quest to grow Canada’s life sciences sector and biomanufacturing capacity including attracting investment and talent to the sector.”

The 2022-2023 BIOTECanada Board of Directors

• Gordon C. McCauley, President and CEO AdMare BioInnovations (Chair)
• Roberto Bellini, President & CEO, Bellus Health (Vice Chair)
• Oliver Technow, CEO, BioVectra Inc. (Treasurer)
• Andrew Casey, President & CEO, BIOTECanada (Secretary)
• Norma Biln, CEO, Augurex
• Neal Carter, President & Founder, Okanagan Specialty Fruits
• Andrew Haigh, President and CEO, Adapsyn Bioscience
• Alok Kanti, General Manager, Bayer Canada
• Melissa Koomey, Vice President & General Manager, Gilead Sciences Canada
• A.J. (Sandy) Marshall, Chairman, Bioindustrial Innovation Canada
• Paul Petrelli, President & CEO, Jazz Pharmaceuticals
• Tracey Ramsay, Vice President and General Manager, AbbVie Canada
• Sanj Singh, President & CEO, Temple Therapeutics B.V.
• Jamie Stiff, Managing Director, Genesys Capital
• Ali Tehrani, Partner, Amplitude Ventures

 

Contacts

[email protected]
613-793-6338